公司資料
Beyond Air 股價、新聞與催化劑
- 股票代碼:
- XAIR
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
5.71 USD (-9.58%)
收盤價
最後更新: 2026年8月17日
5.97M USD
市值
股價為何變動
As of Aug 17, 2026, XAIR closed down 9.58% at $5.71. No new same-company headline was identified in the current news window.
公司概覽
Nitric Oxide Medical Technology Platform
Beyond Air is a commercial-stage medical device and biopharmaceutical company developing nitric oxide-based products for respiratory disease, neurological conditions, and solid tumors. Its first product, LungFit PH, is FDA-approved and CE-marked for hypoxic respiratory failure in term and near-term newborns.
Cylinder-Free LungFit System
LungFit is a phasic-flow nitric oxide generation and delivery system that produces nitric oxide from ambient air without high-pressure cylinders. The design reduces cylinder inventory, storage requirements, and nitrogen dioxide venting while simplifying hospital operations.
Commercial and International Reach
Beyond Air is commercializing LungFit PH in the United States and through a distribution network covering more than 45 countries. Regional partners provide regulatory and market access beyond the company’s direct U.S. organization.
Second-Generation Product Strategy
The second-generation LungFit PH is designed to be smaller, lighter, easier to operate, and suitable for a broader range of care settings. The updated system is also intended to support patient transport use.
Nitric Oxide Platform Beyond Respiratory Care
Beyond Air is also exploring nitric oxide biology in neurological disease and solid tumors. These programs extend the company’s technology base beyond hospital respiratory delivery, although LungFit PH remains its commercial foundation.
未來催化劑
- An FDA decision is pending on the PMA supplement for the second-generation LungFit PH system.
- The PMA supplement also seeks an expanded label covering use during air and ground patient transport.
- Regional regulatory submissions for LungFit PH continue through local partners, with future approvals determining the scope of international commercialization.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。